Statement of Ownership (sc 13g)
February 12 2021 - 8:04AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
|
Washington, D.C. 20549
|
|
SCHEDULE 13G
|
|
Under the Securities Exchange Act of 1934
|
(Amendment No. __)*
|
|
Genocea Biosciences,
Inc.
|
(Name of Issuer)
|
|
Common Stock,
par value $0.001 per share
|
(Title of Class of Securities)
|
|
372427401
|
(CUSIP Number)
|
|
December
31, 2020
|
(Date of Event Which Requires Filing of This Statement)
|
|
|
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
|
|
þ
|
Rule 13d-1(b)
|
¨
|
Rule 13d-1(c)
|
¨
|
Rule 13d-1(d)
|
|
(Page 1 of 8 Pages)
|
______________________________
*The remainder of this cover page shall
be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
CUSIP No. 372427401
|
13G
|
Page 2 of 8 Pages
|
1
|
NAME OF REPORTING PERSON
Avoro Capital Advisors LLC
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ¨
(b) þ
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
|
5
|
SOLE VOTING POWER
33,613,444 (including 28,529,260 shares of Common Stock
issuable upon exercise of Warrants) (see Item 4)*
|
6
|
SHARED VOTING POWER
0
|
7
|
SOLE DISPOSITIVE POWER
33,613,444 (including 28,529,260 shares of Common Stock
issuable upon exercise of Warrants) (see Item 4)*
|
8
|
SHARED DISPOSITIVE POWER
0
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
33,613,444 (including 28,529,260 shares of Common Stock
issuable upon exercise of Warrants) (see Item 4)*
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99% (see Item 4)*
|
12
|
TYPE OF REPORTING PERSON
OO, IA
|
|
|
|
|
|
* As more fully described in Item 4, the Warrants (as defined below)
are subject to the 9.99% Blocker (as defined below) and the percentage set forth in row (11) gives effect to such blocker. However,
rows (5), (7) and (9) show the number of shares of Common Stock that would be issuable upon the exercise in full of the Warrants
and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting
Person, after giving effect to such blocker, is less than the number of securities reported in rows (5), (7) and (9).
CUSIP No. 372427401
|
13G
|
Page 3 of 8 Pages
|
1
|
NAME OF REPORTING PERSON
Behzad Aghazadeh
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) ¨
(b) þ
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
|
5
|
SOLE VOTING POWER
33,613,444 (including 28,529,260 shares of Common Stock
issuable upon exercise of Warrants) (see Item 4)*
|
6
|
SHARED VOTING POWER
0
|
7
|
SOLE DISPOSITIVE POWER
33,613,444 (including 28,529,260 shares of Common Stock
issuable upon exercise of Warrants) (see Item 4)*
|
8
|
SHARED DISPOSITIVE POWER
0
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
33,613,444 (including 28,529,260 shares of Common Stock
issuable upon exercise of Warrants) (see Item 4)*
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99% (see Item 4)*
|
12
|
TYPE OF REPORTING PERSON
IN
|
|
|
|
|
|
* As more fully described in Item 4, the Warrants are subject to
the 9.99% Blocker and the percentage set forth in row (11) gives effect to such blocker. However, rows (5), (7) and (9) show the
number of shares of Common Stock that would be issuable upon the exercise in full of the Warrants and do not give effect to such
blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect
to such blocker, is less than the number of securities reported in rows (5), (7) and (9).
CUSIP No. 372427401
|
13G
|
Page 4 of 8 Pages
|
Item 1(a).
|
NAME OF ISSUER
|
|
|
|
Genocea Biosciences, Inc. (the "Issuer")
|
Item 1(b).
|
ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
|
|
|
|
100 Acorn Park Drive, Cambridge, Massachusetts 02140
|
Item 2(a).
|
NAME OF PERSON FILING
|
|
|
|
This statement is filed by: (i) Avoro Capital
Advisors LLC, a Delaware limited liability company ("Avoro"), which provides investment advisory and management
services and has acquired the securities of the Issuer solely for investment purposes on behalf of Avoro Life Sciences Fund LLC,
a Delaware limited liability company, and certain managed accounts and (ii) Behzad Aghazadeh ("Dr. Aghazadeh,"
and together with Avoro, the "Reporting Persons"), who serves as the portfolio manager and controlling person
of Avoro.
The filing of this statement should not be construed
as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported
herein.
|
Item 2(b).
|
ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
|
|
|
|
The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012.
|
Item 2(c).
|
CITIZENSHIP
|
|
|
|
Avoro is a Delaware limited liability company. Dr. Aghazadeh is a United States citizen.
|
Item 2(d).
|
TITLE OF CLASS OF SECURITIES
|
|
|
|
Common Stock, par value $0.001 per share (the "Common Stock")
|
Item 2(e).
|
CUSIP NUMBER
|
|
|
|
372427401
|
CUSIP No. 372427401
|
13G
|
Page 5 of 8 Pages
|
Item 3.
|
IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
|
|
(a)
|
¨
|
Broker or dealer registered under Section 15 of the Act;
|
|
(b)
|
¨
|
Bank as defined in Section 3(a)(6) of the Act;
|
|
(c)
|
¨
|
Insurance company as defined in Section 3(a)(19) of the Act;
|
|
(d)
|
¨
|
Investment company registered under Section 8 of the Investment Company Act of 1940;
|
|
(e)
|
þ
|
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
|
|
(f)
|
¨
|
An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
|
|
(g)
|
þ
|
A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
|
|
(h)
|
¨
|
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
|
|
(i)
|
¨
|
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
|
|
(j)
|
¨
|
A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
|
|
(k)
|
¨
|
Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
|
|
If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),
please
specify
the type of institution: ________________________________
|
Item 4.
|
OWNERSHIP
|
|
|
|
The information required by Items 4(a) - (c) is set forth in Rows
5 - 11 of the cover page and is incorporated herein by reference.
The percentage set forth in Row 11 of this Schedule 13G is calculated
based upon 51,635,257 shares of Common Stock outstanding as of October 27, 2020, as reported in the Issuer's Quarterly Report on
Form 10-Q for the quarterly period ended September 30, 2020 filed with the Securities and Exchange Commission on October 29, 2020
and assumes the exercise of certain warrants (the "Warrants") to purchase Common Stock of the Company held by Avoro Life
Sciences Fund LLC subject to the 9.99% Blocker.
Pursuant to the terms of the Warrants, the Reporting Persons cannot
exercise the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the
outstanding shares of Common Stock (the "9.99% Blocker") and the percentage set forth in Row (11) of the cover page for
each Reporting Person gives effect to the 9.99% Blocker. Consequently, at this time, the Reporting Persons are not able to exercise
all of such Warrants due to the 9.99% Blocker.
|
CUSIP No. 372427401
|
13G
|
Page 6 of 8 Pages
|
Item 5.
|
OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
|
|
|
|
Not applicable.
|
Item 6.
|
OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
|
|
|
|
See Item 2. Avoro Life Sciences Fund LLC has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock.
|
Item 7.
|
IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
|
|
|
|
Not applicable.
|
Item 8.
|
IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
|
|
|
|
Not applicable.
|
Item 9.
|
NOTICE OF DISSOLUTION OF GROUP
|
|
|
|
Not applicable.
|
|
Each Reporting Person hereby makes the following certification:
|
|
|
|
By signing below the Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
|
|
|
CUSIP No. 372427401
|
13G
|
Page 7 of 8 Pages
|
SIGNATURES
After reasonable
inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in
this statement is true, complete and correct.
DATE: February 12, 2021
AVORO CAPITAL ADVISORS LLC
|
|
|
|
|
|
/s/ Scott Epstein
|
|
Name: Scott Epstein
|
|
Title: Chief Financial Officer
& Chief Compliance Officer
|
|
|
|
/s/ Behzad Aghazadeh
|
|
BEHZAD AGHAZADEH
|
|
CUSIP No. 372427401
|
13G
|
Page 8 of 8 Pages
|
EXHIBIT 1
JOINT FILING AGREEMENT
PURSUANT TO RULE 13d-1(k)
The undersigned
acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent
amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing
additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments,
and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible
for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason
to believe that such information is inaccurate.
DATE: February 12, 2021
AVORO CAPITAL ADVISORS LLC
|
|
|
|
|
|
/s/ Scott Epstein
|
|
Name: Scott Epstein
|
|
Title: Chief Financial Officer
& Chief Compliance Officer
|
|
|
|
/s/ Behzad Aghazadeh
|
|
BEHZAD AGHAZADEH
|
|
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Sep 2023 to Sep 2024